What is a possible PEP regimen using Truvada (emtricitabine/tenofovir disoproxil fumarate) and raltegravir for a patient with potential HIV exposure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Truvada Plus Raltegravir is an Acceptable PEP Regimen

You have a CDC-recommended post-exposure prophylaxis regimen: Truvada (tenofovir disoproxil fumarate/emtricitabine) plus raltegravir 400mg twice daily for 28 days is explicitly endorsed as a preferred option. 1, 2

Dosing Specifics

  • Administer Truvada (TDF 300mg/FTC 200mg) one tablet once daily PLUS raltegravir 400mg twice daily (every 12 hours) for a complete 28-day course 1, 2

  • Initiate this regimen immediately without waiting for source patient HIV confirmation or resistance testing results 1

  • The twice-daily dosing of raltegravir is critical—this is NOT the once-daily formulation 1

Timing and Initiation

  • Start PEP as soon as possible, ideally within 1-2 hours but up to 72 hours post-exposure for optimal effectiveness 2, 3

  • Even if you're approaching or slightly beyond the 72-hour window, initiate treatment for high-risk exposures as some benefit may still exist, particularly with well-tolerated modern regimens 3

Baseline Assessment Required

  • Obtain HIV antibody/antigen combination testing (ideally fourth-generation) before starting 1, 2

  • Check baseline serum creatinine with calculated creatinine clearance 2

  • Perform sexually transmitted infection screening (gonorrhea, chlamydia, syphilis) 1, 2

  • Obtain hepatitis B and C serologies 1, 2

  • Pregnancy test for individuals of childbearing potential 1, 2

Follow-Up HIV Testing Schedule

  • Reassess HIV serostatus at 4-6 weeks, 3 months, and 6 months after exposure 1, 2

  • If using a fourth-generation assay, shorter serologic follow-up at 3-4 months may be acceptable 1

  • Discontinue PEP if the source patient is confirmed HIV-negative at any point 3

Important Clinical Caveats

  • Adherence is absolutely critical—counsel the patient that missing doses significantly reduces efficacy 2

  • The twice-daily raltegravir dosing can be challenging; consider setting phone alarms or using pill organizers 1

  • Monitor for gastrointestinal side effects (nausea, diarrhea) and headache, though this regimen is generally well-tolerated 4

  • Raltegravir requires administration without regard to food, while Truvada can be taken with or without food 1

Transition Consideration

  • For individuals with repeated PEP requests or ongoing high-risk exposures, transition to daily PrEP (Truvada once daily) after completing the 28-day PEP course, as continuous PrEP may provide superior protection compared to episodic PEP 1, 2

Why This Regimen Works

  • While newer single-tablet regimens like bictegravir/emtricitabine/tenofovir alafenamide show higher completion rates (90-96%) 5, 6, your available combination of Truvada plus twice-daily raltegravir remains a CDC-preferred option with established efficacy 1, 2

  • The combination provides coverage against wild-type HIV with minimal resistance concerns when used for PEP 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HIV Prophylaxis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Post-Exposure Prophylaxis Initiated Beyond the Recommended 72-Hour Window

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

BIC/FTC/TAF for HIV Post-Exposure Prophylaxis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.